Cartalax Research for Age-Related Joint Decline
An evidence-based overview of research examining Cartalax in the context of age-related joint decline. This page synthesizes findings from peer-reviewed literature.
Research Summary
Within the Khavinson bioregulator framework, Cartalax is positioned to address age-related cartilage changes. Russian research proposes anti- senescence effects including reduction of cellular aging markers (p16, p21, p53) and upregulation of the longevity-associated protein SIRT-6 in chondrocyte-relevant cell populations. These claims derive from general short-peptide bioregulator research applied to cartilage tissues. No human clinical trials have evaluated effects on age-related joint decline. All evidence is theoretical extrapolation from preclinical models.
Referenced Studies
Click any PMID to view the full study on PubMed.
Other Peptides Studied for Age-Related Joint Decline
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Cartalax has not received regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.